In vitro controlled drug delivery of cationic substituted hydroxyapatite nanoparticles; enhanced anti-chelating and antibacterial response
Hydroxyapatite (HAp) is naturally found in the bones and is used to deliver antimicrobials and antibacterial agents such as chlorhexidine and gentamicin to the bone. The unique ability of hydroxyapatite crystalline lattice regarding the substitution of calcium ions with an excessive cationic species is being widely explored for utilization in nanoscale biomedicine. This study covers, the in vitro controlled drug delivery of cationic substituted hydroxyapatite (Nix=0.3,0.5 HAp) nanoparticles loaded with widely consumed drug, ciprofloxacin. Our results indicate that the cationic substitution of nickel in Hydroxyapatite increased the percentage of ciprofloxacin loading and release in a controlled mode of action. Cationic substituted hydroxyapatite (Nix=0.3,0.5 HAp) nanoparticles loaded with ciprofloxacin have shown antioxidant activity, prolonged release of ciprofloxacin and strong antibacterial activity against Escherichia coli (ATCC 35218) and Pseudomonas aeruginosa (ATTC 27853) strains. The Antibacterial properties of the Nickel and ciprofloxacin doped Hydroxyapatite along with sustained and prolonged release of Hydroxyapatite associated ciprofloxacin would be helpful for effective management and prevention of osteomyelitis and dental infections due to Escherichia coli and Pseudomonas aeruginosa.